German patent setback for GlaxoSmithKline’s Seretide
pharmafile | May 21, 2010 | News story | Sales and Marketing | GSK, Germany, Seretide
A Munich court has ruled GlaxoSmithKline’s combination patent for its asthma and COPD treatment Seretide is not valid.
The Federal Patents Court agreed with three generic firms, Mylan, Novartis’ Hexal unit and Teva’s subsidiary Ivax International, that the combination patent for Viani (as Seretide is marketed in Germany) was not valid under German law.
The case related to the combination of two active ingredients, salmeterol and fluticasone propionate, used in the inhaled treatment.
The decision only affects Viani’s combination product in Germany, not GSK’s other German patents for the treatment.
These include a Diskus dry powder and an HFA aerosol formulation, patents for which remain in force until 2011 and 2012 respectively.
Meanwhile, GSK says it is studying the decision on Viani’s combination product patent and will consider appealing to a higher court.
Ben Adams
Related Content

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis
GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …

Multiple myeloma treatment approved in Japan
GSK’s Blenrep (belantamab mafodotin) combinations have been approved by Japan’s Ministry of Health, Labour and …

US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit
PHILADELPHIA–GSK plc today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination …






